- Home
- BUJA vs IKNA Comparison
BUJA vs IKNA Comparison
Compare BUJA & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- IKNA
- Stock Information
- Founded
- BUJA 2022
- IKNA 2016
- Country
- BUJA Malaysia
- IKNA United States
- Employees
- BUJA N/A
- IKNA N/A
- Industry
- BUJA Blank Checks
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- IKNA Health Care
- Exchange
- BUJA Nasdaq
- IKNA Nasdaq
- Market Cap
- BUJA N/A
- IKNA 83.0M
- IPO Year
- BUJA 2023
- IKNA 2021
- Fundamental
- Price
- BUJA $10.96
- IKNA $1.68
- Analyst Decision
- BUJA
- IKNA Buy
- Analyst Count
- BUJA 0
- IKNA 2
- Target Price
- BUJA N/A
- IKNA $3.00
- AVG Volume (30 Days)
- BUJA 2.7K
- IKNA 41.6K
- Earning Date
- BUJA 01-01-0001
- IKNA 11-07-2024
- Dividend Yield
- BUJA N/A
- IKNA N/A
- EPS Growth
- BUJA N/A
- IKNA N/A
- EPS
- BUJA 0.29
- IKNA N/A
- Revenue
- BUJA N/A
- IKNA $1,844,000.00
- Revenue This Year
- BUJA N/A
- IKNA N/A
- Revenue Next Year
- BUJA N/A
- IKNA N/A
- P/E Ratio
- BUJA $37.13
- IKNA N/A
- Revenue Growth
- BUJA N/A
- IKNA N/A
- 52 Week Low
- BUJA $10.30
- IKNA $1.02
- 52 Week High
- BUJA $12.18
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- BUJA 67.66
- IKNA 51.57
- Support Level
- BUJA $10.85
- IKNA $1.68
- Resistance Level
- BUJA $10.85
- IKNA $1.78
- Average True Range (ATR)
- BUJA 0.00
- IKNA 0.04
- MACD
- BUJA -0.00
- IKNA 0.00
- Stochastic Oscillator
- BUJA 87.50
- IKNA 36.36
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.